Received a Notified Body Clinical Finding?
Bioexcel helps medical device manufacturers interpret Notified Body findings, identify the underlying evidence gap and build a structured remediation pathway across CER, PMCF, PMS, equivalence, GSPR, Risk Management and clinical studies.
Where documentation alone is not enough, Bioexcel can also support the additional clinical evidence needed to address the underlying deficiency.
Reduce Avoidable Notified Body Clock-Stops
Incomplete evidence, inconsistent documentation and unclear responses can interrupt conformity-assessment timelines. Bioexcel evaluates the complete evidence chain to identify the underlying issue and prepare a coordinated response across affected clinical, performance, risk-management and post-market documents.
Bioexcel Support
A secure document-upload field connects this page to the Discuss Your Project form.
Can Bioexcel Help With Notified Body Findings?
Yes. Bioexcel supports Notified Body remediation by reviewing the exact finding, identifying the regulatory and clinical evidence gap, revising affected documentation and supporting additional evidence generation where necessary.
Bioexcel Lifesciences & Research LLP is a specialized medical device and IVD clinical research organization supporting Notified Body clinical evidence remediation across CER, PMCF, PMS, equivalence, GSPR, Risk Management and additional clinical evidence generation.
The Comment May Be in the CER, but the Root Cause May Be Elsewhere
A finding can appear to concern one document while actually reflecting inconsistencies across several evidence sources. For example, a CER finding may originate from:
- Weak GSPR traceability
- Unsupported clinical claims
- Inadequate equivalence
- Generic PMCF
- Weak PMS interpretation
- Risk Management inconsistency
- Insufficient long-term evidence
- Outdated state of the art
Therefore, Bioexcel reviews the whole evidence chain, not only the paragraph highlighted by the reviewer.
What Should a Manufacturer Do First After Receiving a Notified Body Finding?
The first step is to interpret the exact wording of the finding against the applicable regulatory requirement, identify the affected evidence and documents, and determine whether the issue is a documentation gap, an analysis gap or a genuine clinical evidence gap.
From Finding to Submission-Ready Response
Finding Interpretation
- Exact finding wording
- Regulatory basis
- Affected document
- Evidence referenced
- Submission deadline
- Priority
Output: Finding Interpretation Matrix
Root-Cause Gap Assessment
- CER
- CEP
- PMCF
- PMS
- PSUR
- Risk Management
- GSPR
- SSCP
- Literature
- Clinical investigations
Output: Root-Cause Analysis
Gap Classification
- Documentation gap
- Analysis gap
- Evidence gap
- Consistency gap
Output: Gap Category
Corrective Strategy
- Document update
- Literature update
- SOTA strengthening
- Equivalence reassessment
- PMS analysis
- PMCF revision
- New clinical evidence
Output: Remediation Plan
Evidence Strengthening
- New literature search
- Additional statistical analysis
- PMCF analysis
- GSPR mapping
- Risk alignment
- Benefit-risk reassessment
Output: Strengthened Evidence Package
Document Remediation
- CEP
- CER
- PMCF Plan
- PMCF Evaluation Report
- PMS
- PSUR
- Risk Management
- SSCP
Output: Revised Documents
Response Matrix
- Finding
- Requirement
- Root cause
- Corrective action
- Updated section
- Evidence reference
Output: Finding-by-Finding Response
Final Consistency Review
- Confirm alignment across the evidence lifecycle
Output: Submission-Ready Remediation Package
What Notified Body remediation services does Bioexcel provide?
Bioexcel provides Notified Body finding interpretation, clinical evidence gap assessment, CER and PMCF remediation, equivalence reassessment, GSPR mapping, PMS/Risk Management alignment and additional clinical evidence strategy.
Can Bioexcel support both documentation and new clinical evidence?
Yes. Bioexcel can support document remediation and, where necessary, execute prospective, retrospective, PMCF or other clinical evidence programs.
Does Bioexcel guarantee Notified Body acceptance?
No. Bioexcel supports evidence strengthening and response preparation, while final regulatory decisions remain with the relevant conformity-assessment body.
Is the Problem Documentation, Analysis or Missing Evidence?
Documentation Gap
Evidence exists, but it is:
- Poorly presented
- Poorly linked
- Inconsistently referenced
- Not traceable
Analysis Gap
Evidence exists, but:
- No trend analysis was performed
- No statistical interpretation exists
- Benefit-risk was not reassessed
- PMCF was not clinically interpreted
Clinical Evidence Gap
Required evidence is genuinely missing. Potential response:
- Prospective clinical investigation
- Prospective PMCF
- Retrospective PMCF
- Registry
- Real-world evidence
Consistency Gap
Documents contradict each other. Examples:
- CER vs Risk Management
- PMS vs PSUR
- PMCF vs CER
- SSCP vs CER
Does Every Notified Body Finding Require a New Clinical Study?
No. Many findings can be addressed through stronger analysis, traceability, literature review, PMCF interpretation or cross-document remediation. A new study is needed only when the underlying clinical evidence remains genuinely insufficient.
Notified Body Findings Against Clinical Evaluation
Common Issues
- Insufficient device-specific clinical evidence
- Weak literature methodology
- Outdated SOTA
- Unsupported claims
- Weak equivalence
- Missing GSPR linkage
- Poor PMS integration
- Generic PMCF
- Weak benefit-risk
- Risk Management inconsistencies
Bioexcel Support
- CER gap assessment
- CEP revision
- Literature update
- Appraisal update
- SOTA revision
- Equivalence reassessment
- GSPR mapping
- PMS/PMCF integration
- Benefit-risk strengthening
Can Bioexcel Fix a CER Nonconformity?
Yes. Bioexcel can perform a finding-by-finding CER gap assessment, identify the underlying evidence or methodology issue and support targeted remediation of the CER and related clinical evidence documents.
Notified Body PMCF Deficiencies
Common Issues
- PMCF Plan too generic
- No clear evidence gap
- No specific clinical objective
- Inappropriate study method
- Survey-only strategy without justification
- Insufficient follow-up
- PMCF results not integrated into CER
- No link to Risk Management
- No long-term evidence
Bioexcel Support
- PMCF gap assessment
- Revised PMCF strategy
- PMCF Plan update
- Prospective PMCF
- Retrospective PMCF
- Registry
- PMCF Evaluation Report
- CER integration
Can Retrospective PMCF Help Resolve a Notified Body Finding?
Potentially yes. If historical hospital records contain reliable clinical data relevant to the specific evidence gap, a properly designed retrospective PMCF study may form part of the remediation strategy.
When Equivalence Is Challenged
Common Issues
- Technical characteristics not sufficiently comparable
- Biological characteristics inadequately addressed
- Clinical characteristics not aligned
- Differences not clinically justified
- Inadequate access to equivalent-device data
- Similarity presented as equivalence
Bioexcel Support
- Equivalence reassessment
- Technical comparison
- Biological comparison
- Clinical comparison
- Difference analysis
- Data-access review
- Alternative evidence strategy
Can Bioexcel Reassess Equivalence Under EU MDR?
Yes. Bioexcel can reassess technical, biological and clinical equivalence and determine whether the existing evidence strategy remains supportable or whether alternative device-specific evidence should be generated.
Clinical Evidence Traceability to GSPRs
- GSPRs requiring clinical evidence not identified
- No clear evidence mapping
- Clinical conclusions unsupported
- CER and GSPR checklist inconsistent
Weak SOTA Can Undermine the Entire Clinical Evaluation
Common Issues
- Outdated references
- Missing guidelines
- No clinical alternatives
- No device alternatives
- No performance benchmark
- No safety benchmark
- No accepted clinical outcome range
Bioexcel Can Strengthen
- Clinical condition background
- Treatment pathway
- Guidelines
- Alternative interventions
- Similar devices
- Safety benchmarks
- Performance benchmarks
- Clinical benefit expectations
Literature Methodology Must Be Transparent
Potential Deficiencies
- Search not reproducible
- Databases not justified
- Search terms weak
- Screening unclear
- Appraisal weak
- Device literature missing
- SOTA literature incomplete
- Exclusion reasons not transparent
Bioexcel Support
- Literature Search Protocol
- Updated search
- Screening
- PRISMA
- Appraisal
- Evidence tables
- CER integration
Post-Market Data Need Clinical Interpretation
A Notified Body may challenge PMS where the manufacturer reports counts without interpreting clinical relevance. Bioexcel can evaluate:
- Sales / exposure
- Complaints
- Serious incidents
- Complaint rates
- Trends
- CAPA
- FSCA
- Emerging signals
- PMCF findings
- Benefit-risk impact
PSUR Should Align With the Clinical Evidence Story
Potential Issues
- Exposure not adequately defined
- Complaint trends not interpreted
- PMCF omitted
- New risks not reflected
- Benefit-risk inconsistent
- CER and PSUR conclusions differ
Bioexcel Support
- Clinical consistency review
- Trend interpretation
- PMCF integration
- CER cross-check
- Risk Management alignment
CER and Risk Management Should Agree on Clinical Risk
- Risk listed in RMF but absent from CER
- Frequency differs between documents
- PMCF does not assess important residual risks
- Benefit-risk conclusions conflict
- New post-market risks are not integrated
Public Clinical Information Should Match the Technical Documentation
- Clinical benefit differs from CER
- Residual risk inconsistent
- PMCF not updated
- Device indications differ
- Safety conclusions not aligned
Bioexcel can review SSCP clinical content against the underlying evidence.
When Existing Clinical Study Evidence Is Challenged
Possible Findings
- Inappropriate endpoint
- Weak sample-size rationale
- Inadequate follow-up
- Study population not representative
- Comparator concerns
- Statistical methodology concerns
- Missing data
- Protocol deviations
- Limited device applicability
Bioexcel Support
- Study appraisal
- Statistical review
- Endpoint justification
- Limitation analysis
- Additional PMCF strategy
- New clinical investigation design
Some Findings Cannot Be Solved by Rewriting the Document
If the evidence itself is insufficient, possible strategies include:
Prospective Clinical Investigation
For structured pre-market or confirmatory evidence.
Prospective PMCF
For targeted post-market outcomes.
Retrospective PMCF
For existing long-term hospital data.
Registry
For ongoing longitudinal evidence.
Real-World Evidence
For relevant routine-care data.
Can Bioexcel Conduct the Additional Study if the Notified Body Requires More Evidence?
Yes. If remediation identifies a genuine clinical evidence gap, Bioexcel can support the design and execution of prospective clinical investigations, PMCF, retrospective studies, registries and other appropriate evidence-generation programs.
Make Every Corrective Action Traceable
Developer should show a sample matrix:
| Finding | Requirement | Root Cause | Corrective Action | Evidence | Updated Document |
|---|---|---|---|---|---|
| NB-01 | Clinical evidence | Evidence gap | New analysis | PMCF dataset | CER Rev. X |
| NB-02 | Traceability | Documentation gap | GSPR mapping | Evidence matrix | CEP/CER |
| NB-03 | PMCF Strategy | Strategy gap | Revised PMCF | PMCF Plan | PMCF Rev. X |
Bioexcel Deliverables
One Corrective Action May Require Several Document Updates
Example:
Bioexcel assesses the downstream impact before finalizing the response.
Find the Gaps Before the Notified Body Does
Bioexcel can perform a clinical evidence readiness review before submission.
Deliverable
EU MDR Clinical Evidence Gap Assessment
Suggested Output
- Critical gaps
- Major gaps
- Improvement opportunities
- Recommended corrective action
- Priority
- Document owner
- Evidence requirement
Working Against a Regulatory Deadline?
Bioexcel can structure remediation work around:
Can Bioexcel Review a Notified Body Response Prepared by Another Consultant?
Yes. Bioexcel can independently review an existing response package, assess whether the corrective action actually addresses the root cause and identify remaining clinical evidence or consistency gaps before resubmission.
What Should the Sponsor Share?
Where available:
- Notified Body finding letter
- CER
- CEP
- PMCF Plan
- PMCF Evaluation Report
- PMS Plan
- PSUR
- Risk Management File
- GSPR checklist
- SSCP
- Clinical Investigation Report
- Literature Search Report
- Equivalence assessment
- IFU
- Device description
Connected Clinical Evidence Services
Why Manufacturers Use Bioexcel for Notified Body Remediation
Root-Cause Approach
The objective is to solve the underlying problem, not only rewrite the answer.
Clinical + Regulatory Integration
CER, PMCF, PMS, Risk Management and GSPR are reviewed together.
Evidence Generation Capability
If new evidence is required, Bioexcel can support the study.
Medical Device Specialization
Remediation is approached from a MedTech clinical evidence perspective.
Finding-by-Finding Traceability
Each response is linked to updated evidence and documents.
Flexible Scope
One finding or complete clinical documentation remediation.
EU MDR CER Nonconformity Resolution – Urology Portfolio
A medical device manufacturer received Notified Body findings across multiple CERs.
Key Issues
- Literature required strengthening
- Equivalence needed improvement
- State-of-the-art alignment required revision
- PMS and Risk Management linkage was weak
- Benefit-risk conclusions required stronger support
Bioexcel's Approach
- Finding-by-finding gap assessment
- Literature review strengthening
- Improved traceability
- Equivalence reassessment
- SOTA update
- PMS integration
- Risk Management linkage
- Benefit-risk revision
Outcome: The affected clinical evidence package was updated for regulatory resubmission.
Frequently Asked Questions About Notified Body Findings
A Notified Body nonconformity or finding identifies an area where the submitted technical or clinical documentation does not adequately demonstrate conformity with the applicable requirement.
Bioexcel addresses the clinical evidence problem behind the finding—not just the response letter.